首页> 外文期刊>European Journal of Pharmacology: An International Journal >Unilateral lesion of the nigroestriatal pathway with 6-OHDA induced allodynia and hyperalgesia reverted by pramipexol in rats
【24h】

Unilateral lesion of the nigroestriatal pathway with 6-OHDA induced allodynia and hyperalgesia reverted by pramipexol in rats

机译:用6-OHDA诱导的Allodycnia和Hyprapsia在大鼠恢复的单侧病变

获取原文
获取原文并翻译 | 示例
           

摘要

Pain is the non-motor symptom with the highest prevalence in patients with Parkinson's Disease (PD) affecting 40-85%. This study aimed to investigate the development of tactile allodynia and mechanical hyperalgesia after the nigrostriatal dopaminergic lesion induced by the unilateral 6-hydroxydopamine (6-OHDA) injection at different doses in the substantia nigra pars compacta (SNpc). Moreover, we studied the possible antiallodynic and antihyperalgesic effect with the acute and the subacute treatment of the pramipexole (PPX) in rats. First, dopaminergic lesion was realized by the unilateral injection of 6-OHDA (6, 10 and 16 mu g/mu l) into the SNpc. To know the establishment of motor deficits, we measure several turns and forelimb-use asymmetry by rotational behavior and cylinder, respectively. On the other hand, to investigate allodynia and hyperalgesia induced by 6-OHDA, we used the von Frey filaments. Moreover, antiallodynic and antihyperalgesic effect induced by PPX (0.03, 0.3 and 3 mg/kg, s.c.) was examined on acute and subacute conditions. We found that major dopaminergic lesion with 16 mu g/mu l of 6-OHDA caused the highest allodynia and hyperalgesia effects in both paws, as well as the major motor deficits. In addition, the treatment with PPX at 0.3 mg/kg reverts the allodynia and the hyperalgesia induced by 6-OHDA. In conclusion, the dopaminergic lesion into SNpc induce allodynia and hyperalgesia in both paws; interestingly the treatment with PPX can be suggested as an analgesic drug for patients with PD.
机译:疼痛是帕金森病(PD)患者患有最高患病率的非运动症状,影响40-85%。本研究旨在探讨单侧6-羟基多胺(6-OHDA)注射患者在实质内菌诱导的单侧乙虫多巴胺病变之后触觉异常疼痛和机械痛觉疗高痛苦的发展。此外,我们研究了大鼠普氏蛋白酶(PPX)的急性和亚急性治疗可能的抗衰弱性和抗震性效果。首先,通过单侧注射6-OHDA(6,10和16μg/ mu L)来实现多巴胺能物质,进入SNPC。要了解机动缺陷的建立,我们分别通过旋转行为和气缸测量多个转弯和前肢使用不对称。另一方面,为了调查6-OHDA诱导的异常疼痛和痛觉,我们使用了冯弗雷丝。此外,通过PPX(0.03,0.3和3mg / kg,S.C.)诱导的抗微弱和抗静电效果在急性和亚急性条件下检查。我们发现,具有16μg/ mu L 6-Ohda的主要多巴胺能病变引起了两种爪子的最高病症和痛觉过敏症,以及主要的电机缺陷。此外,用PPX处理0.3mg / kg的治疗恢复了6-OHDA诱导的异常性疼痛和痛觉痛觉。总之,多巴胺能病变进入SNPC诱导两只爪子的异常性疼痛和痛觉过敏;有趣地,可以提出PPX的治疗作为PD患者的镇痛药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号